%0 Journal Article
%A Wankhede, Durgesh
%A Bontoux, Christophe
%A Grover, Sandeep
%A Hofman, Paul
%T Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
%J Diagnostics
%V 13
%N 19
%@ 2075-4418
%C Basel
%I MDPI
%M DKFZ-2023-02074
%P 3043
%D 2023
%Z #EA:C070#
%X KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct KRAS G12C inhibitors in advanced solid cancers. We sought to determine the prognostic significance of mKRAS G12C in patients with NSCLC using the meta-analytic approach. A protocol is registered at the International Prospective Register for systematic reviews (CRD42022345868). PubMed, EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were searched for prospective or retrospective studies reporting survival data for tumors with mKRAS G12C compared with either other KRAS mutations or wild-type KRAS (KRAS-WT). The hazard ratios (HRs) for overall survival (OS) or Disease-free survival (DFS) of tumors were pooled according to fixed or random-effects models. Sixteen studies enrolling 10,153 participants were included in the final analysis. mKRAS G12C tumors had poor OS [HR, 1.42; 95
%K KRAS (Other)
%K KRAS G12C (Other)
%K NSCLC (Other)
%K meta-analysis (Other)
%K non-small cell lung cancer (Other)
%K systematic review (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37835787
%2 pmc:PMC10572143
%R 10.3390/diagnostics13193043
%U https://inrepo02.dkfz.de/record/284763